Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Intellectual property legal development expenses
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept amrx:IntellectualPropertyLegalDevelopmentExpenses.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — intellectual property legal development expenses of $1.49M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses decreased by 12.8% year-over-year, from $1.71M to $1.49M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — intellectual property legal development expenses has grown at a 20.2% compound annual growth rate (CAGR), from $4.25M to $7.39M.
- What does affordable medicines — intellectual property legal development expenses mean?
- Tracks the legal costs associated with securing, defending, and maintaining intellectual property rights for products within the Affordable Medicines segment. These expenses are critical for protecting the company's competitive advantage and market exclusivity.